UNI Venture Group advances international, sovereign-aligned pharmaceutical manufacturing platforms across the U.S. and partner jurisdictions, with active work-streams focused on governance, financing, and regulatory sequencing.
As we enter 2026, the platform is entering preparatory stages for the next phase of its buy-side process. Select industry participants have been notified of evolving developments, and broader formal engagement will follow the completion of governance and structural milestones.
This update reflects an end-of-year progress update following prior public disclosures related to this initiative.
Happy New Year.
